Filing Flows › Acadia Pharmaceuticals (ACAD) › Q1 2026
Acadia Pharmaceuticals (ACAD) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Acadia Pharmaceuticals (ACAD) reported revenue of $268M for the first quarter 2026 (Q1 2026), +10% from a year earlier and -6% from the quarter before. Operating margin was -1.7%, net earnings $3.6M (1.4% of revenue).
Acadia Pharmaceuticals, Q1 2026: revenue $268M (+10% year over year), operating margin -1.7%, net earnings $3.6M, operating cash flow $34.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $268M | -6% | +10% |
| Operating profit | −$4.6M | -127% | -124% |
| Net earnings | $3.6M | -99% | -81% |
| Operating cash flow | $34.0M | — | +67% |
| Free cash flow | $28.8M | — | +42% |
What changed
Revenue was $268.1M in Q1 2026, up 10% year over year and down 6% from the previous quarter.
Operating costs exceeded revenue by $4.6M, an operating margin of -1.7%. Total costs grew 21% against revenue growth of 10%. The fastest-growing cost line was SG&A (+35%). Net earnings were $3.6M, down 81% year over year. The effective tax rate was 8.6%. Non-operating items added $8.6M, 216% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $34.0M (up 67% year over year), 934% of net earnings. Non-cash charges added back $3.0M of depreciation and amortization and $14.7M of share-based compensation. Working capital and other items added $12.7M. Capital expenditures of $5.2M left free cash flow of $28.8M.
Questions
What was Acadia Pharmaceuticals' revenue in the first quarter 2026?
Acadia Pharmaceuticals (ACAD) reported revenue of $268M for the first quarter 2026 (Q1 2026), +10% from a year earlier and -6% from the quarter before.
Was Acadia Pharmaceuticals profitable in the first quarter 2026?
Operating loss was $4.6M (-1.7% of revenue) and net earnings $3.6M.